This network meta-analysis of 601 trials, including individual participant data from 103 trials, assessed whether the efficacy of 3 newer drug classes (SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors) varied by age or sex in people with type 2 diabetes. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.